Nicole Casasanta, MD
@ncasasanta.bsky.social
Heme/Onc Fellow @YaleCancer | Aspiring Breast Oncologist interested in clinical/translational research
🔍HER2 PARADIGM Trial now enrolling
🔹HER2-0 and HER2-0+ pts with MBC
🔹s/p 1 line of therapy
➡️T-DXd until progression
🎯 HER2 & TROP2 Quantitative immunofluorescence on biopsy sample
NCT06750484
Love working with this outstanding
Yale Breast & @yalepathology.bsky.social team!
@yalecancer.bsky.social
🔹HER2-0 and HER2-0+ pts with MBC
🔹s/p 1 line of therapy
➡️T-DXd until progression
🎯 HER2 & TROP2 Quantitative immunofluorescence on biopsy sample
NCT06750484
Love working with this outstanding
Yale Breast & @yalepathology.bsky.social team!
@yalecancer.bsky.social
December 12, 2025 at 11:21 PM
🔍HER2 PARADIGM Trial now enrolling
🔹HER2-0 and HER2-0+ pts with MBC
🔹s/p 1 line of therapy
➡️T-DXd until progression
🎯 HER2 & TROP2 Quantitative immunofluorescence on biopsy sample
NCT06750484
Love working with this outstanding
Yale Breast & @yalepathology.bsky.social team!
@yalecancer.bsky.social
🔹HER2-0 and HER2-0+ pts with MBC
🔹s/p 1 line of therapy
➡️T-DXd until progression
🎯 HER2 & TROP2 Quantitative immunofluorescence on biopsy sample
NCT06750484
Love working with this outstanding
Yale Breast & @yalepathology.bsky.social team!
@yalecancer.bsky.social
🚨Wisdom Trial🚨
🔹randomized women to risk based bca screening vs annual screening
📍risk based: 9 genes, PRS, BCSC v2 model➡️ 4 risk groups guided frequency of screening
✅ rate of stage IIB ca noninferior to annual screening
🔹rate of breast biopsies was not lower
#SABCS25
🔹randomized women to risk based bca screening vs annual screening
📍risk based: 9 genes, PRS, BCSC v2 model➡️ 4 risk groups guided frequency of screening
✅ rate of stage IIB ca noninferior to annual screening
🔹rate of breast biopsies was not lower
#SABCS25
In WISDOM, researchers compared risk-based breast cancer screening to standard annual mammography among more than 28 000 US women aged 40 to 74 across all 50 states.
#SABCS25 @sabcs.bsky.social
ja.ma/494994l
#SABCS25 @sabcs.bsky.social
ja.ma/494994l
December 12, 2025 at 11:17 PM
🚨Wisdom Trial🚨
🔹randomized women to risk based bca screening vs annual screening
📍risk based: 9 genes, PRS, BCSC v2 model➡️ 4 risk groups guided frequency of screening
✅ rate of stage IIB ca noninferior to annual screening
🔹rate of breast biopsies was not lower
#SABCS25
🔹randomized women to risk based bca screening vs annual screening
📍risk based: 9 genes, PRS, BCSC v2 model➡️ 4 risk groups guided frequency of screening
✅ rate of stage IIB ca noninferior to annual screening
🔹rate of breast biopsies was not lower
#SABCS25
📣lidERA trial📣
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25
December 11, 2025 at 5:15 AM
📣lidERA trial📣
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25
🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years
🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014
🔸Arthralgias similar
📍1st trial to report benefit of SERD in the adjuvant tx
📋Looking forward to further data & other trials including CDK4/6i & SERDs💊
#SABCS25
Reposted by Nicole Casasanta, MD
Powerful message from Dr. Amy Beumer at #SABCS25: It’s time to “fix the toxic friendship” and design dosing with patients—balancing side effects, quality of life, and longevity. @maryamlustberg.bsky.social @sabcs.bsky.social
December 10, 2025 at 11:48 PM
Powerful message from Dr. Amy Beumer at #SABCS25: It’s time to “fix the toxic friendship” and design dosing with patients—balancing side effects, quality of life, and longevity. @maryamlustberg.bsky.social @sabcs.bsky.social
📌Starting #SABCS25 off with a discussion of the Advanced Breast Cancer (ABC) Global Decade Report 📈
🔸improved 5 year OS 26% ➡️33%
🔸improvement in QOL, but 79% report negative QOL
🔸access to care gaps have widened
✅ 10 goals 2025-2035
#bcsm @maryamlustberg.bsky.social
🔸improved 5 year OS 26% ➡️33%
🔸improvement in QOL, but 79% report negative QOL
🔸access to care gaps have widened
✅ 10 goals 2025-2035
#bcsm @maryamlustberg.bsky.social
December 9, 2025 at 4:39 PM
📌Starting #SABCS25 off with a discussion of the Advanced Breast Cancer (ABC) Global Decade Report 📈
🔸improved 5 year OS 26% ➡️33%
🔸improvement in QOL, but 79% report negative QOL
🔸access to care gaps have widened
✅ 10 goals 2025-2035
#bcsm @maryamlustberg.bsky.social
🔸improved 5 year OS 26% ➡️33%
🔸improvement in QOL, but 79% report negative QOL
🔸access to care gaps have widened
✅ 10 goals 2025-2035
#bcsm @maryamlustberg.bsky.social
💡Phenomenal @onclive.bsky.social Fellows Forum ahead of #SABCS25 presenting important research, learning about advancing our careers, and making connections with the future leaders in breast oncology 🤝 thankful for the [email protected] @brianato.bsky.social
December 9, 2025 at 12:49 AM
💡Phenomenal @onclive.bsky.social Fellows Forum ahead of #SABCS25 presenting important research, learning about advancing our careers, and making connections with the future leaders in breast oncology 🤝 thankful for the [email protected] @brianato.bsky.social
📍Thought provoking end to the Lynn Sage Breast Cancer Symposium discussing the goals of de-escalation in low risk, escalation in high risk, and individualized treatment in intermediate risk patients. Thankful for the opportunity to attend!✨#LSBC25 @luriecancer.bsky.social
October 26, 2025 at 4:18 PM
📍Thought provoking end to the Lynn Sage Breast Cancer Symposium discussing the goals of de-escalation in low risk, escalation in high risk, and individualized treatment in intermediate risk patients. Thankful for the opportunity to attend!✨#LSBC25 @luriecancer.bsky.social
💡Fabulous first day of the Lynn Sage Breast Cancer Symposium discussing obesity, sustainability, breast reconstruction, pathology, AI in oncology, approaches to management cans so much more ✨Thank you Lynn Sage for the travel award!💐 #LSBC25 @luriecancer.bsky.social
October 24, 2025 at 1:39 AM
💡Fabulous first day of the Lynn Sage Breast Cancer Symposium discussing obesity, sustainability, breast reconstruction, pathology, AI in oncology, approaches to management cans so much more ✨Thank you Lynn Sage for the travel award!💐 #LSBC25 @luriecancer.bsky.social
Excited to have joined Dr. Winer and Etienne to discuss medical oncology training, the future of oncology, and more! 🎙️🩺 @yalecancer.bsky.social
Yale Fellows Drs. Etienne Leveille + @ncasasanta.bsky.social join Dr. Eric Winer for Yale Cancer Answers to talk about the future of #cancer care and the next generation of oncologists.
🎧 Listen live on WNPR
🍎 Download Apple Podcasts
💻 Watch on YouTube
🎧 Listen live on WNPR
🍎 Download Apple Podcasts
💻 Watch on YouTube
September 14, 2025 at 8:53 PM
Excited to have joined Dr. Winer and Etienne to discuss medical oncology training, the future of oncology, and more! 🎙️🩺 @yalecancer.bsky.social
Yale Heme/Onc fellows riding for our patients, families, and cancer research 🧬 at the 15th annual Closer to Free Ride! 🚴🏼♀️💨 @ctfride.bsky.social @yalecancer.bsky.social
September 6, 2025 at 9:38 PM
Yale Heme/Onc fellows riding for our patients, families, and cancer research 🧬 at the 15th annual Closer to Free Ride! 🚴🏼♀️💨 @ctfride.bsky.social @yalecancer.bsky.social
On September 6, 2025, I’ll be participating in the Closer to Free Ride to to raise funds to support cancer research and care for those who need it most - the patients, the families, and our team @yalecancer.bsky.social and Smilow Cancer Hospital Please consider donating to my ride!🚴🏻♀️
August 4, 2025 at 10:14 PM
On September 6, 2025, I’ll be participating in the Closer to Free Ride to to raise funds to support cancer research and care for those who need it most - the patients, the families, and our team @yalecancer.bsky.social and Smilow Cancer Hospital Please consider donating to my ride!🚴🏻♀️
Amazing talk #ASCO2025 Highlights in MBC @maryamlustberg.bsky.social @yalecancer.bsky.social
📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations
📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations
June 2, 2025 at 4:51 PM
Amazing talk #ASCO2025 Highlights in MBC @maryamlustberg.bsky.social @yalecancer.bsky.social
📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations
📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations
Reposted by Nicole Casasanta, MD
We have great representation in this morning's #ASCO25 poster session in Hall A! Stop by and support our presenters:
Drs. Soki Kashima, Tara Sanft, Zachary Yochum, Ro Malik, @braunmdphd.bsky.social, Aarti Bhatia, @ncasasanta.bsky.social, Jing Du, and Ismail Ajjawi.
@yaleschoolofmed.bsky.social
Drs. Soki Kashima, Tara Sanft, Zachary Yochum, Ro Malik, @braunmdphd.bsky.social, Aarti Bhatia, @ncasasanta.bsky.social, Jing Du, and Ismail Ajjawi.
@yaleschoolofmed.bsky.social
June 2, 2025 at 2:27 PM
We have great representation in this morning's #ASCO25 poster session in Hall A! Stop by and support our presenters:
Drs. Soki Kashima, Tara Sanft, Zachary Yochum, Ro Malik, @braunmdphd.bsky.social, Aarti Bhatia, @ncasasanta.bsky.social, Jing Du, and Ismail Ajjawi.
@yaleschoolofmed.bsky.social
Drs. Soki Kashima, Tara Sanft, Zachary Yochum, Ro Malik, @braunmdphd.bsky.social, Aarti Bhatia, @ncasasanta.bsky.social, Jing Du, and Ismail Ajjawi.
@yaleschoolofmed.bsky.social
🚨Practice changing interim results DESTINY-Breast09 evaluating 1st Line T-DXd + P vs THP in HER2+ MBC
🔹PFS 40.7 m vs 26.9 m!
🔹PFS2 not reached vs 36.5 m
🔹 OS immature
#ASCO2025
🔹PFS 40.7 m vs 26.9 m!
🔹PFS2 not reached vs 36.5 m
🔹 OS immature
#ASCO2025
June 2, 2025 at 1:16 PM
🚨Practice changing interim results DESTINY-Breast09 evaluating 1st Line T-DXd + P vs THP in HER2+ MBC
🔹PFS 40.7 m vs 26.9 m!
🔹PFS2 not reached vs 36.5 m
🔹 OS immature
#ASCO2025
🔹PFS 40.7 m vs 26.9 m!
🔹PFS2 not reached vs 36.5 m
🔹 OS immature
#ASCO2025
Lots of buzz around TBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰
➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%
➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%
June 2, 2025 at 12:02 PM
Lots of buzz around TBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰
➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%
➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%
Innovative SERENA-6 trial: at molecular progression switch to SERD w/ continuation of CDK4/6i in HR+ MBC improved PFS1✅
🔹PFS2 & OS not mature
🔹 Improved TTD in QOL
🔹Control group PFS still 9.2 m
🔹Awaiting data on clearance of ctDNA after switch
#ASCO2025
🔹PFS2 & OS not mature
🔹 Improved TTD in QOL
🔹Control group PFS still 9.2 m
🔹Awaiting data on clearance of ctDNA after switch
#ASCO2025
SERENA-6 phase 3 trial: In patients with advanced breast cancer, switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection (and before disease progression) led to significantly longer progression-free survival. nej.md/4k1dRml
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
June 1, 2025 at 8:37 PM
Innovative SERENA-6 trial: at molecular progression switch to SERD w/ continuation of CDK4/6i in HR+ MBC improved PFS1✅
🔹PFS2 & OS not mature
🔹 Improved TTD in QOL
🔹Control group PFS still 9.2 m
🔹Awaiting data on clearance of ctDNA after switch
#ASCO2025
🔹PFS2 & OS not mature
🔹 Improved TTD in QOL
🔹Control group PFS still 9.2 m
🔹Awaiting data on clearance of ctDNA after switch
#ASCO2025
Inspirational words on positioning yourself for success by these four women physician leaders! Sharing advice with early career women in oncology. Now we have the tools for success🛠️✨#ASCO2025 @maryamlustberg.bsky.social @drgattimays.bsky.social @yalecancer.bsky.social
June 1, 2025 at 5:36 PM
Inspirational words on positioning yourself for success by these four women physician leaders! Sharing advice with early career women in oncology. Now we have the tools for success🛠️✨#ASCO2025 @maryamlustberg.bsky.social @drgattimays.bsky.social @yalecancer.bsky.social
Outstanding talk by Dr. Ian Krop on antibody drug conjugates in the era of targeted therapies. 🔬So much groundbreaking work has been done and there’s still more work to do in understanding mechanism, mechanisms of resistance, and biomarkers for response📈📌 #ASCO2025
June 1, 2025 at 12:26 AM
Outstanding talk by Dr. Ian Krop on antibody drug conjugates in the era of targeted therapies. 🔬So much groundbreaking work has been done and there’s still more work to do in understanding mechanism, mechanisms of resistance, and biomarkers for response📈📌 #ASCO2025
Reposted by Nicole Casasanta, MD
INAVO120 trial: In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. nej.md/3Zje7Vt
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
May 31, 2025 at 12:04 PM
INAVO120 trial: In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. nej.md/3Zje7Vt
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
Reposted by Nicole Casasanta, MD
In advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with ESR1 mutations but not in the full patient population. Full VERITAC-2 phase 3 trial results: nej.md/3ZoCL7g
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
May 31, 2025 at 12:09 PM
In advanced breast cancer, progression-free survival was significantly longer with vepdegestrant than with fulvestrant among patients with ESR1 mutations but not in the full patient population. Full VERITAC-2 phase 3 trial results: nej.md/3ZoCL7g
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
Impressive & practice changing ASCENT-04/KEYNOTE-D19 evaluating sacituzumab go ite an + pembro vs chemo + pembro in 1st Line PDL1+ metastatic TNBC demonstrating PFS 11.2 vs 7.8 months! 🚨Much needed improvement in 1st Line metastatic TNBC #ASCO2025
May 31, 2025 at 11:01 PM
Impressive & practice changing ASCENT-04/KEYNOTE-D19 evaluating sacituzumab go ite an + pembro vs chemo + pembro in 1st Line PDL1+ metastatic TNBC demonstrating PFS 11.2 vs 7.8 months! 🚨Much needed improvement in 1st Line metastatic TNBC #ASCO2025
Reposted by Nicole Casasanta, MD
Congratulations to our faculty and fellows on their awards from @conquercancer.bsky.social at #ASCO25!
(l-r) Drs. Mariya Rozenblit, @ncasasanta.bsky.social, Devora Isseroff and Benjamin Lu.
Learn more ➡️ yalecancercenter.org/news-article...
@ascocancer.bsky.social @yaleschoolofmed.bsky.social
(l-r) Drs. Mariya Rozenblit, @ncasasanta.bsky.social, Devora Isseroff and Benjamin Lu.
Learn more ➡️ yalecancercenter.org/news-article...
@ascocancer.bsky.social @yaleschoolofmed.bsky.social
May 31, 2025 at 3:41 PM
Congratulations to our faculty and fellows on their awards from @conquercancer.bsky.social at #ASCO25!
(l-r) Drs. Mariya Rozenblit, @ncasasanta.bsky.social, Devora Isseroff and Benjamin Lu.
Learn more ➡️ yalecancercenter.org/news-article...
@ascocancer.bsky.social @yaleschoolofmed.bsky.social
(l-r) Drs. Mariya Rozenblit, @ncasasanta.bsky.social, Devora Isseroff and Benjamin Lu.
Learn more ➡️ yalecancercenter.org/news-article...
@ascocancer.bsky.social @yaleschoolofmed.bsky.social
Great start to #ASCO2025 with Yale Cancer Center and at the @conquercancer.bsky.social
Awards Ceremony🏆 So grateful to have the opportunity to research improved biomarkers for ADC response in patients with HER2-low, HER2-ultralow, and HER2 0 breast cancer 🔬🩺
Awards Ceremony🏆 So grateful to have the opportunity to research improved biomarkers for ADC response in patients with HER2-low, HER2-ultralow, and HER2 0 breast cancer 🔬🩺
May 31, 2025 at 12:09 AM
Great start to #ASCO2025 with Yale Cancer Center and at the @conquercancer.bsky.social
Awards Ceremony🏆 So grateful to have the opportunity to research improved biomarkers for ADC response in patients with HER2-low, HER2-ultralow, and HER2 0 breast cancer 🔬🩺
Awards Ceremony🏆 So grateful to have the opportunity to research improved biomarkers for ADC response in patients with HER2-low, HER2-ultralow, and HER2 0 breast cancer 🔬🩺
Looking forward to seeing the data for neoadjuvant T-DXd ➡️ THP in patients with high risk, locally advanced HER2+ breast cancer! 💉
Rates of ILD similar among T-DXd/THP vs ddAC-THP arms🫁
Rates of ILD similar among T-DXd/THP vs ddAC-THP arms🫁
NEWS FROM INDUSTRY🚨 Source AstraZeneca
DESTINY-Breast11 Update
DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen
www.astrazeneca.com/media-centre...
DESTINY-Breast11 Update
DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen
www.astrazeneca.com/media-centre...
May 8, 2025 at 12:55 AM
Looking forward to seeing the data for neoadjuvant T-DXd ➡️ THP in patients with high risk, locally advanced HER2+ breast cancer! 💉
Rates of ILD similar among T-DXd/THP vs ddAC-THP arms🫁
Rates of ILD similar among T-DXd/THP vs ddAC-THP arms🫁